Entrada Therapeutics has secured authorisation from the UK MHRA to commence Phase I/II trial of ENTR-601-45 for treating DMD.

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.

The Clinical Trials Arena team investigates the impact of government research funding cuts on biopharma and biotech running ...

Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...

Today marks World TB Day 2025 with the WHO calling for more investment into TB treatment and research globally.

MUSC Hollings Cancer Center, US, has enrolled the first subject in the trial of ficerafusp alfa to treat individuals with HPV ...

The AUR87A study found that urine collected biomarkers could accurately predict recurrence of kidney cancer in post-surgery ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...